Chip-Based Blood Test Accurately Diagnoses Heart Attack in Minutes
|
By LabMedica International staff writers Posted on 17 Oct 2024 |

Heart attacks demand immediate medical attention to improve patient outcomes; however, while early diagnosis is crucial, it can be quite challenging—and nearly impossible outside of a clinical environment. Diagnosing heart attacks remains one of the most difficult tasks due to the wide variability of symptoms and subtle biological signals that can be easily overlooked in the early stages of an attack when medical intervention can be most beneficial. Individuals suspected of experiencing a heart attack typically undergo a series of tests to confirm the diagnosis, usually beginning with electrocardiograms that measure the heart's electrical activity—a procedure that takes about five minutes—and blood tests to identify the indicators of a heart attack, where lab results can take at least an hour and often require repetition. A new blood test has now been developed that can diagnose a heart attack in minutes rather than hours, and it has the potential to serve as a tool for first responders and individuals at home.
Researchers at Johns Hopkins University (Baltimore, MD, USA) have published their proof-of-concept work in Advanced Science, which can be modified to detect infectious diseases and cancer biomarkers. The focus of the research has been on developing diagnostic tools through biophotonics, utilizing laser light to identify biomarkers—bodily responses to various conditions, including diseases. In this instance, they applied the technology to detect the earliest signs in the blood that indicate a heart attack. The stand-alone blood test created by the team yields results in just five to seven minutes. They claim it is also more accurate and cost-effective than current methods.
Although initially designed for rapid diagnostic use in a clinical setting, the test could be adapted into a hand-held device for use by first responders in the field or even for personal use at home. Central to the invention is a small chip featuring a groundbreaking nanostructured surface for blood testing. The chip's "metasurface" amplifies electric and magnetic signals during Raman spectroscopy analysis, enabling heart attack biomarkers to be detected in seconds, even at ultra-low concentrations. This tool is sensitive enough to identify heart attack biomarkers that might not be detected by existing tests or might only be recognized later in the course of an attack. While primarily intended for diagnosing heart attacks, the researchers believe the tool could also be modified to detect cancer and infectious diseases. The team plans to refine the blood test further and undertake larger clinical trials in the future.
"We're talking about speed, we're talking about accuracy, and we're talking of the ability to perform measurements outside of a hospital," said Ishan Barman, Professor, Department of Mechanical Engineering. "In the future, we hope this could be made into a hand-held instrument like a Star Trek tricorder, where you have a drop of blood and then, voilà, in a few seconds you have detection."
Latest Technology News
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
Channels
Clinical Chemistry
view channelAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read more
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read moreMolecular Diagnostics
view channel
Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Patented Isothermal Amplification Chemistry Advances Decentralized Testing
Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more
Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more
Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








